Pembrolizumab Shows Benefit for NSCLC Patients with Brain Metastases
The results showed that even patients with disease that has spread to the brain should be considered for immunotherapy.
Treatment with Durvalumab May Lead to Pneumonitis
One-third of patients with locally advanced non-small cell lung cancer treated with durvalumab developed symptomatic pneumonitis.
Phase III CANOPY Studies to Investigate Canakinumab in NSCLC
The agent has a high affinity and specificity for interleukin-1 beta.
Metformin Increases Glucose Uptake in Early-Stage NSCLC
Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.
Sequential TKI Treatment Improves OS in EGFR T790M-Positive NSCLC
October 12, 2019
Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.
Neutrophil-to-Lymphocyte Ratio Helps Predict Survival in Stage III NSCLC
October 12, 2019
NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.
Can This Biomarker-Based Screening Identify More Early-Stage Lung Cancers?
September 17, 2019
A new study presented at the International Association for the Study of Lung Cancer's 2019 conference may have found a model for lung cancer screening which improves on lung cancer screening guidelines from the U.S. Preventive Services Task Force.
Outcomes With Video-Assisted vs Open Surgery in Lung Cancer
September 11, 2019
Video-assisted thoracic surgery (VATS) results in fewer in-hospital complications and a shorter length of stay compared with open surgery in patients with early-stage lung cancer.
Extending Survival in Extensive-Stage Small-Cell Lung Cancer
September 11, 2019
In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.
Evaluating the Safety of Immunotherapy in NSCLC Patients With Comorbidities
September 10, 2019
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.
